Allergy Immunotherapy Market Share

North America Market Insights

The North America allergy immunotherapy market is anticipated to account for more than 40.5% of the global market share by the end of 2035. The dominance of the region is attributable to a large patient pool and strong support from the country’s government, which is with their funding initiatives. Additionally, the increased awareness about the allergic conditions of immunotherapy and the advancements in sublingual immunotherapy are significantly contributing to the market growth in the region. Furthermore, the growing adoption of personalized medicine and favourable reimbursement policies are shaping market expansion.

The allergic immunotherapy market in the U.S. is driven by rising disease prevalence, and private sector investments in the medical industry. For instance, based on the CDC report in January 2023, 1 in 3 adults and more than 1 in 4 children in the U.S. reported having a seasonal allergy. Moreover, 6% of adults and children have a food allergy, showcasing the demand in the market. Hence, such factors are expected to support the market progression during the forecast period with enhanced treatment access.

Allergy Types and their Prevalences

Sources: ACAAI, AACI Journal, Food Allergy Canada, Canada Government, NLM October 2023

APAC Market Insights

The allergy immunotherapy market is the fastest-growing market in the Asia-Pacific region and is experiencing significant growth, driven by increasing prevalence of allergic diseases, rising healthcare expenditure, and government-associated initiatives in countries such as Japan, China, India, South Korea, and Malaysia. Additionally, the rapid urbanization is creating a large patient pool owing to the increased pollution, which creates a heightened awareness of healthcare access in the region.  The region’s market is projected to grow steadily with support from governments to drive further growth.

China is a global leader in the market, which is exceptionally supported by increasing instances of allergic diseases in the country. As per the NLM article in November 2022, nearly 250 million people in China are affected by allergic rhinitis. Furthermore, as the population increases, the demand for management strategies also expands rapidly. Those factors strengthen the domestic production of allergy immunotherapy products in the country, positioning China as a key leader in the Asia Pacific.

Europe Market Insights

The allergy immunotherapy market in Europe is expanding rapidly and is dominated by high disease prevalence, advanced healthcare systems, and robust government support. The major drivers are the mass adoption of both subcutaneous (SCIT) and sublingual (SLIT) therapies, facilitated by solid national reimbursement systems in Germany and France. One notable trend is the convergence of regulatory approvals within the European Union, which is enabled by the European Medicines Agency (EMA) that expedites market access for novel AIT products. In addition, rising patient awareness, supplemented by clinical guidelines that support the use of AIT as a disease-modifying treatment, is driving demand.

Germany is projected to hold the largest revenue share in Europe by 2035. The region is dominated by its strong statutory health insurance system, which provides high coverage and timely reimbursement for both SCIT and SLIT therapies, ensuring high patient access. According to the NLM report in July 2023, 15% of the adult population and 10% of children are suffering from allergic rhinitis. In addition, the nation's large patient base, high diagnostic rates, and dense network of specialized allergologists cement its market leadership even further.